The clinical update serves as a brief review of recently published, high-impact, and potentially practice-changing journal articles summarized for our readers. Topics include menopause, sexual dysfunction, breast health, contraception, osteoporosis, and cardiovascular disease. In this clinical update, we selected recent publications relevant to the use of contraceptive methods. We highlight articles on continuation rates of long-acting reversible contraception versus nonlong-acting methods, updated risks of intrauterine devices, use of estrogen-containing contraceptives during anticoagulation for venous thromboembolic events, and the efficacy of oral and emergency contraception in women with elevated body mass index.
Get full access to this article
View all access options for this article.
References
1.
Centers for Disease Control and Prevention. U S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control, 2010; 59:1–86.
2.
American College of Obstetrics and Gynecology. Committee opinion No. 642: Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol, 2015; 126:e44–e48.
3.
KavanaughML, JermanJ, FinerLB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009–2012. Obstet Gynecol, 2015; 126:917–927.
4.
TealSB, RomerSE, GoldthwaiteLM, et al.Insertion characteristics of intrauterine devices in adolescents and young women: Success, ancillary measures, and complications. Am J Obstet Gynecol, 2015; 213:515.e1–e5.
5.
American Academy of Pediatrics. Contraception for adolescents. Pediatrics, 2014:134:e1257–e1281.
6.
Van HoudenhovenK, van KaamKJAF, van GrootheestAC, SalemansTHB, DunselmanGAJ. Uterine perforation in women using a levonorgestrel-releasing intrauterinesystem. Contraception, 2006; 73:257–260.
7.
CaliskanE, OztürkN, DilbazBO, et al.Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care, 2003; 8:150–155.
8.
BaglinT, BauerK, DouketisJ, et al.SSC of the ISTH. Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: Guidance from the SSC of the ISTH. J Thromb Haemost. 2012; 10:698–702.
9.
RoachRE, HelmerhorstFM, LijferingWM, StijnenT, AlgraA, DekkersOM. Combined oral contraceptives: The risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev, 2015; 8:CD011054.
10.
American College of Obstetrics and Gynecology. Practice Bulletin No. 110: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol, 2010; 1551:206–218.
11.
LotkeMS, KaneshiroB. Safety and efficacy of contraceptive methods for obese and overweight women. Obstet Gynecol Clin N Am, 2015; 42:647–657.
12.
LopezLM, GrimesDA, ChenM, et al.Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev, 2013 ( Issue 4).
13.
McNicholasC, ZhaoQ, SecuraG, AllsworthJE, MaddenT, PeipertJF. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol, 2013; 121:585–592.
14.
BensonLS, MicksEA. Why stop now? Extended and continuous regimens of combined hormonal contraceptive methods. Obstet Gynecol Clin North Am, 2015; 42:669–681.
15.
GlasierA, CameronST, BlitheD, et al.Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception, 2011; 84:363–367.
16.
BaturP, ClelandK, McNamaraM, WuJ, PickleS. EC Survey Group. Emergency contraception: A national, multi-specialty survey of clinician knowledge and practices. Contraception, 2016; 93:145–152.
17.
American College of Obstetrics and Gynecology. Practice bulletin summary No. 152: Emergency contraception. Obstet Gynecol, 2015; 126:685–686.
